



IFW

PATENT  
Attorney Docket No. 04012.0384-00000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Lukas-Laskey et al.	)	Group Art Unit: 1614
	)	
Application No.: 10/721,022	)	Examiner: P. Spivack
	)	
Filed: November 25, 2003	)	
	)	
For: USE OF CARBAZOLE COMPOUNDS	)	Confirmation No.: 3995
FOR THE TREATMENT OF	)	
CONGESTIVE HEART FAILURE	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**REPLY TO OFFICE ACTION**

The Office Action dated January 23, 2007, has been received and its contents carefully considered. Reconsideration and withdrawal of the rejections set forth in that Action are respectfully requested in view of the following remarks.

**I. Rejections under 35 U.S.C. §§ 102, 103**

Claim 9 was rejected under 35 U.S.C. § 102(a) as allegedly anticipated by Metra (Metra et al., Journal of the American College of Cardiology 24(7), pg. 1678-87 (Dec. 1994)). (Office Action, pg. 2.) Claims 1-8 and 10-30 were rejected under 35 U.S.C. § 103(a) over Olsen (Olsen et al., Journal of the American College of Cardiology, Vol. 21, No. 2:141A, Abstract 725-2 (February 1993)) in view of Metra. (Office Action, pg. 3.) Only Metra is cited for allegedly disclosing reduction in a risk of mortality in patients suffering from congestive heart failure ("CHF"). (Office Action, pg. 2, 4.)